We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

muscle disease

Advertisement

cGxPJobs Banner

Edgewise Advances Muscle and Heart Disease Pipeline

BOULDER, Colo., May 7, 2026 Edgewise Therapeutics reported first quarter 2026 financial results while highlighting major progress across its...

By cGxPwire Editor
May 8, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

.Clinical

Harbour BioMed Receives FDA IND Clearance for HBM7004 Solid Tumor Trial
May 9, 2026
02

.Clinical

Rznomics Announces FDA RMAT Designation for RZ-001 in Hepatocellular Carcinoma
May 9, 2026
03

.Clinical

CardiolRx Phase II Results Support Heart Disease Therapy
May 8, 2026
04

MedTech

ArteraAI Breast Gains FDA Clearance for Cancer Risk
May 8, 2026
05

Bio-Pharma

GSK Signs $1B SiranBio siRNA Cardiometabolic Deal
May 8, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website